Ingunn Sivertsen, Author at Vaccibody.com
-1
archive,author,author-ingunns,author-6,bridge-core-2.4.3,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-23.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive

Vaccibody AS today announced positive results from the phase I part of the clinical trial VB C-01. This trial is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by...

Vaccibody AS announced today vaccination of the first patient in its phase IIa study – an exploratory, open-label, multicenter study with VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). The phase I part of...

Vaccibody AS announces today that inclusion of patients in the expansion phase (phase IIa) of its multicentre trial VB C-01 can be initiated as the company was informed by Paul-Ehrlich Institut („PEI“), the German regulatory authorities, that an amendment to the IMPD (Investigational Medicinal Product...